Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
暂无分享,去创建一个
W. Sandborn | J. Panés | Subrata Ghosh | C. Su | I. Vranic | W. Niezychowski | S. Rousell
[1] B. Strober,et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study , 2012, The British journal of dermatology.
[2] J. Friedewald,et al. Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] J. Kremer,et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.
[4] E. Lee,et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. , 2012, The New England journal of medicine.
[5] Yoshiya Tanaka,et al. Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2011, Arthritis care & research.
[6] W. Sandborn,et al. Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease , 2011 .
[7] John J. O’Shea,et al. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.
[8] S. Schreiber,et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.
[9] Joel Z Stengel,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.
[10] M. Hines,et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. , 2010, Journal of medicinal chemistry.
[11] D. Morris,et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis , 2010, Journal of Inflammation.
[12] W. Weimar,et al. The Jak Inhibitor CP‐690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[14] G. Chan,et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. , 2009, The Journal of investigative dermatology.
[15] David Gruben,et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.
[16] W. Bemelman,et al. European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .
[17] M. Munchhof,et al. The specificity of JAK3 kinase inhibitors. , 2008, Blood.
[18] M. Dougados,et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.
[19] S. Carding,et al. Inflammatory bowel disease: cause and immunobiology , 2007, The Lancet.
[20] W. Sandborn,et al. Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.
[21] Philippe Marteau,et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.
[22] A. Moss,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.
[23] A. Akobeng. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Journal of pediatric gastroenterology and nutrition.
[24] W. Tremaine,et al. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. , 2006, Revista de gastroenterologia de Mexico.
[25] M. Säemann,et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor , 2004, European Surgery.
[26] P. Munkholm,et al. Course of ulcerative colitis: analysis of changes in disease activity over years. , 1994, Gastroenterology.
[27] J. Rochon,et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.
[28] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.